Chemoembolization Combined with RFA for HCC:Survival Benefits and Tumor Treatment Response


Purpose: To investigate survival benefits and tumor treatment response among patients who received treatment with transarterial chemoembolization (TACE) combined with radiofrequency ablation (RFA) and TACE alone. Materials and Methods: A total of 108 HCC patients were treated with TACE between the period of 1998 and 2008. 51 (47.2%) received TACE followed by planned RFA and 57 (52.8%) received TACE alone. 57 patients received Precision TACE with Doxorubicin drug eluting beads and 51 received conventional TACE. Survival analysis was performed using Kaplan Meier Estimator with a log rank test, Fischer exact test was performed for categorical variables and the t test for continuous variables. Results: Mean MELD (Model for End Stage Liver Disease) score among the TACE-RFA and TACE-only groups were 12.87 and 12.33 respectively (p = 0.64). The number of patients in Child’s Class A, B, C in the two groups were 28/15/8 and 23/23/11 (p = 0.30); in Okuda Class I, II and III in the two groups were 22/23/6 and 14/30/9 (p = 0.2). Median survival among patients who received TACE-RFA and TACE alone were 566 days and 209 days (p = 0.01). Median survival of patients treated with Precision-TACE + RFA was 566 days and that of patients treated with conventional TACE + RFA was 336 days (p = 0.510). Mean progression-free duration by RECIST criteria among the TACE + RFA group was 210 days vs. TACE only group 97 days (p = 0.04). Conclusion: Combination therapies of TACE and RFA were associated with improved overall survival than TACE alone. Patients with single tumors <5 cm appeared to have a survival advantage with combination therapy when compared to larger tumors. TACE-RFA was associated with improved tumor response and progression-free duration than TACE alone.

Share and Cite:

R. Dhanasekaran, V. Khanna, D. Kooby, J. Kauh, J. Carew and H. Kim, "Chemoembolization Combined with RFA for HCC:Survival Benefits and Tumor Treatment Response," Journal of Cancer Therapy, Vol. 4 No. 2, 2013, pp. 493-499. doi: 10.4236/jct.2013.42060.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] R. Dhanasekaran, A. Limaye and R. Cabrera, “Hepatocellular Carcinoma: Current Trends in Worldwide Epidemiology, Risk Factors, Diagnosis, and Therapeutics,” Hepatic Medicine: Evidence and Research, Vol. 4, 2012, pp. 19-37.
[2] Surveillance Research Program, “National Cancer Institute. Fast Stats: An Interactive Tool for Access to SEER Cancer Statistics,” 2012.
[3] W. T. Kassahun, J. Fangmann, J. Harms, J. Hauss and M. Bartels, “Liver Resection and Transplantation in the Management of Hepatocellular Carcinoma: A Review,” Experimental and Clinical Transplantation, Vol. 4, No. 2, 2006, pp. 549-558.
[4] Y. S. Guan and Y. Liu, “Interventional Treatments for Hepatocellular Carcinoma,” Hepatobiliary & Pancreatic Diseases International, Vol. 5, No. 4, 2006, pp. 495-500.
[5] M. Schwartz, S. Roayaie and M. Konstadoulakis, “Strategies for the Management of Hepatocellular Carcinoma,” Nature Clinical Practice Oncology, Vol. 4, No. 7, 2007, pp. 424-432.
[6] H. B. El-Serag, J. A. Marrero, L. Rudolph and K. R. Reddy, “Diagnosis and Treatment of Hepatocellular Carcinoma,” Gastroenterology, Vol. 134, No. 6, 2008, pp. 1752-1763.
[7] S. G. Christos, E. R. Douglas, S. Stephen and H. G. JeanFrancois, “New Nonsurgical Therapies in the Treatment of Hepatocellular Carcinoma,” Techniques in Vascular and Interventional Radiology, Vol. 4, No. 3, 2001, pp. 193-199. doi:10.1016/S1089-2516(01)90025-3
[8] A. Lubienski, M. Simon, K. Lubienski, J. Gellissen, R. T. Hoffmann, T. F. Jakobs, et al., “Update on Chemoinfusion and Chemoembolization Treatments,” Radiologe, Vol. 47, No. 12, 2007, pp. 1097-1106, 1108.
[9] K. S. Chok, K. K. Ng, R. T. P. Poon, C. M. Lam, J. Yuen, W. K. Tso, et al., “Comparable Survival in Patients with Unresectable Hepatocellular Carcinoma Treated by Radiofrequency Ablation or Transarterial Chemoembolization,” Archives of Surgery, Vol. 141, No. 12, 2006, pp. 1231-1236. doi:10.1001/archsurg.141.12.1231
[10] B. Q. Cheng, C. Q. Jia, C. T. Liu, W. Fan, Q. L. Wang, Z. L. Zhang, et al., “Chemoembolization Combined with Radiofrequency Ablation for Patients with Hepatocellular Carcinoma Larger than 3 cm: A Randomized Controlled Trial,” JAMA, Vol. 299, No. 14, 2008, pp. 1669-1677.
[11] D. Gasparini, M. Sponza, A. Marzio, R. Zanardi, M. Bazzocchi and Y. Cemal, “Combined Treatment, TACE and RF Ablation, in HCC: Preliminary Results,” La Radiologia Medica (Torino), Vol. 104, No. 5-6, 2002, pp. 412-420.
[12] G. S. Liao, C. Y. Yu, M. L. Shih, D. C. Chan, Y. C. Liu, J. C. Yu, et al., “Radiofrequency Ablation after Transarterial Embolization as Therapy for Patients with Unresectable Hepatocellular Carcinoma,” European Journal of Surgical Oncology, Vol. 34, No. 1, 2008, pp. 61-66.doi:10.1016/j.ejso. 2007.02.006
[13] A. Veltri, P. Moretto, A. Doriguzzi, E. Pagano, G. Carrara and G. Gandini, “Radiofrequency Thermal Ablation (RFA) after Transarterial Chemoembolization (TACE) as a Combined Therapy for Unresectable Non-Early Hepatocellular Carcinoma (HCC),” European Radiology, Vol. 16, No. 3, 2006, pp. 661-669. doi:10.1007/s00330-005-0029-9
[14] R. Lencioni and L. Crocetti, “Image-Guided Thermal Ablation of Hepatocellular Carcinoma,” Critical Reviews in Oncology/Hematology, Vol. 66, No. 3, 2008, pp. 200-207. doi:10.1016/j.critrevonc .2008.01.003
[15] S. Rossi, F. Garbagnati, R. Lencioni, H. P. Allgaier, A. Marchiano, F. Fornari, et al., “Percutaneous Radio-Frequency Thermal Ablation of Nonresectable Hepatocellular Carcinoma after Occlusion of Tumor Blood Supply,” Radiology, Vol. 217, No. 1, 2000, pp. 119-126.
[16] M. Bloomston, O. Binitie, E. Fraiji, M. Murr, E. Zervos, S. Goldin, et al., “Transcatheter Arterial Chemoembolization with or without Radiofrequency Ablation in the Management of Patients with Advanced Hepatic Malignancy,” The American Journal of Surgery, Vol. 68, No. 9, 2002, pp. 827-831.
[17] K. Yamakado, A. Nakatsuka, M. Akeboshi, K. Shiraki, T. Nakano and K. Takeda, “Combination Therapy with Radiofrequency Ablation and Transcatheter Chemoembolization for the Treatment of Hepatocellular Carcinoma: Short-Term Recurrences and Survival,” Oncology Reports, Vol. 11, No. 1, 2004, pp. 105-109.
[18] A. R. Padhani and L. Ollivier, “The RECIST (Response Evaluation Criteria in Solid Tumors) Criteria: Implications for Diagnostic Radiologists,” British Journal of Radiology, Vol. 74, No. 887, 2001, pp. 983-986.
[19] C. C. Jaffe, “Measures of Response: RECIST, WHO, and New Alternatives,” Journal of Clinical Oncology, Vol. 24, No. 20, 2006, pp. 3245-3251. doi:10.1200/JCO.2006.06.5599
[20] P. K. Julka, D. C. Doval, S. Gupta and G. K. Rath, “Response Assessment in Solid Tumours: A Comparison of WHO, SWOG and RECIST Guidelines,” British Journal of Radiology, Vol. 81, No. 966, 2008, pp. 444-449. doi:10.1259/bjr/32785946
[21] R. Dhanasekaran, D. A. Kooby, C. A. Staley, J. S. Kauh, V. Khanna and H. S. Kim, “Prognostic Factors for Survival in Patients with Unresectable Hepatocellular Carcinoma Undergoing Chemoembolization with Doxorubicin Drug-Eluting Beads: A Preliminary Study,” HPB, Vol. 12, No. 3, 2010, pp. 174-180. doi:10.1111/j.1477-2574.2009.00138.x
[22] W. Wang, J. Shi and W. F. Xie, “Transarterial Chemoembolization in Combination with Percutaneous Ablation Therapy in Unresectable Hepatocellular Carcinoma: A MetaAnalysis,” Liver International: Official Journal of the International Association for the Study of the Liver, Vol. 30, No. 5, 2010, pp. 741-749.
[23] T. Kagawa, J. Koizumi, S. Kojima, N. Nagata, M. Numata, N. Watanabe, et al., “Transcatheter Arterial Chemoembolization plus Radiofrequency Ablation Therapy for Early Stage Hepatocellular Carcinoma: Comparison with Surgical Resection,” Cancer, Vol. 116, No. 15, 2010, pp. 3638-3644.
[24] R. Dhanasekaran, D. A. Kooby, C. A. Staley, J. S. Kauh, V. Khanna and H. S. Kim, “Comparison of Conventional Transarterial Chemoembolization (TACE) and Chemoembolization with Doxorubicin Drug Eluting Beads (DEB) for Unresectable Hepatocelluar Carcinoma (HCC) ,” Journal of Surgical Oncology, Vol. 101, No. 6, 2010, pp. 476-480.
[25] D. I. Giuseppe, A. Muneeb, D. G. Geoffrey, E. S. Keith, B. K. Jonathan, F. H. Elkan, et al., “Percutaneous Tumor Ablation: Reduced Tumor Growth with Combined Radio-Frequency Ablation and Liposomal Doxorubicin in a Rat Breast Tumor Model,” Radiology, Vol. 228, No. 1, 2003, pp. 112-118. doi:10.1148/radiol.2281020358
[26] A. Muneeb, E. M. Wayne, G. Geoffrey, L. Anatoly, D. I. Giuseppe, B. K. Jonathan, et al., “Radiofrequency Thermal Ablation Sharply Increases Intratumoral Liposomal Doxorubicin Accumulation and Tumor Coagulation,” Cancer Research, Vol. 63, No. 19, 2003, pp. 6327-6333.
[27] A. Muneeb, N. L. Anatoly, T. Vladimir, T. Herve, N. S. Anatoly and N. S. Goldberg, “Combined Radiofrequency Ablation and Adjuvant Liposomal Chemotherapy: Effect of Chemotherapeutic Agent, Nanoparticle Size, and Circulation Time,” Journal of Vascular and Interventional Radiology: JVIR, Vol. 16, No. 10, 2005, pp. 1365-1371. doi:10.1097/01.RVI.0000175324.63304.25
[28] L. M. Wayne, B. K. Jonathan, N. L. Anatoly, D. G. Geoffrey, A. Muneeb, G. S. Gazelle, et al., “Radio-Frequency Ablation Increases Intratumoral Liposomal Doxorubicin Accumulation in a Rat Breast Tumor Model,” Radiology, Vol. 224, No. 3, 2002, pp. 823-829. doi:10.1148/radiol.2243011421

Copyright © 2020 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.